Paul
06-05-2003, 03:28 AM
The HERceptin® Adjuvant (HERA) Trial is a large-scale international clinical trial designed to determine if earlier use of the breast cancer drug Herceptin® (trastuzumab) can increase the length of survival without cancer recurrence in women whose early breast cancer has been diagnosed as HER2 positive. The Breast International Group (BIG) and F. Hoffmann-La Roche (Roche) are collaborating to conduct the HERA Trial.
To be eligible to participate in the trial patients must: (i)be diagnosed with primary breast cancer (ii) have been diagnosed as strongly HER2-positive (iii)have completed a course of standard systematic chemotherapy (standard chemotherapy administered before or after surgery) prior to enrolment.
It appears that the HERA trial is being conducted entirely outside the U.S.
To be eligible to participate in the trial patients must: (i)be diagnosed with primary breast cancer (ii) have been diagnosed as strongly HER2-positive (iii)have completed a course of standard systematic chemotherapy (standard chemotherapy administered before or after surgery) prior to enrolment.
It appears that the HERA trial is being conducted entirely outside the U.S.